Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients

Transplantation

Volumn 65, Issue 2, 1998, Pages 248-252

  Roth, David ^a   Colona, Jane ^a   Burke, George W ^a   Ciancio, Gaetano ^a   Esquenazi, Violet ^a   Miller, Joshua ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ARTICLE; CLINICAL FEATURE; DIABETES MELLITUS; DIARRHEA; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY;

EID: 0032570276     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199801270-00018     Document Type: Article

References (20)

1. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996; 61: 1029.
2. Sollinger HW for The U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60: 225.
3. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporine and corticosteroids for prevention of acute rejection. Lancet 1995; 345: 1321.
4. Pirsch JD, Miller J, Deirrhoi MH, Vincenti F, Filo RS for the FK506 Kidney Transplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977.
5. Basadonna GP, Matas AJ, Gillingham KJ, et al. Early vs. late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993; 55: 993.
6. Ferguson R. Acute rejection episodes: best predictor of long-term primary cadaveric renal transplant survival. Clin Transplant 1994; 8: 328.
7. Garcia-Morales R, Carreno M, Mathew J, et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest 1997; 99: 1118.
8. Allesiani M, Spada M, Dionigi P, et al. Combined immunosuppressive therapy with tacrolimus and mycophenolate mofetil for small bowel transplantation in pigs. Transplantation 1996; 62: 563.
9. Regazzi MB, Alessiani P, Gatti S, et al. Pharmacokineties of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. Transplant Proc 1997; 29(3): 1857.
10. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of tacrolimus/prednisone versus tracrolimus/ prednisone/mycophenolate mofetil in cadaveric renal transplantation: first report [Abstract]. Proceedings of the 16th annual meeting of the American Society of Transplant Physicians, May 11-16, 1997, Chicago, IL.
11. Stratta RJ for the FK/MMF Multi-Center Study Group. Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. Transplant Proc 1997; 29(1-2): 654.
12. Zucker K, Rosen A, Tsaroucha A, et al. Augmentation of mycophenolate mofetil pharmacokinetics in renal transplant patients receiving Prograf and Cellcept in combination therapy. Transplant Proc 1997; 29(1-2): 334.
13. Tomlanovich S, Cho S, Hodge E, Miller J, Neylan J, Hooftman L. Mycophenolate mofetil in cadaveric renal transplantation: 3 year data [Abstract]. Proceedings of the 16th annual meeting of the American Society of Transplant Physicians, May 11-16, 1997, Chicago, IL.
14. Jordan ML, Shapiro R, Vivas CA, et al. FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 1994; 57: 860.
15. Scantlebury V, Shapiro R, Fung J, et al. New onset diabetes in FK506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 1991; 23: 3169.
16. Shapiro R, Jordan M, Fung J, et al. Kidney transplantation under FK506 immunosuppression. Transplant Proc 1991; 23: 920.
17. Shapiro R, Jordan ML, Scantlebury VP, et al. A prospective, randomized trial of FK506/prednisone vs. FK506/azathioprine/ prednisone in renal transplant patients. Transplant Proc 1995; 27: 814.
18. Yamamoto H, Akazawa S, Yamaguchi Y, et al. Effects of cyclosporine A and low dosages of steroids on posttransplantation diabetes in kidney transplant recipients. Diabetes Care 1991; 14: 867.
19. Von Kiparski A, Frei D, Uhlschmid G, et al. Post-transplant diabetes mellitus in renal allograft recipients: a matched pair control study. Nephrol Dial Transplant 1990; 5: 220.
20. Krentz AJ, Dmitrewski J, Mayer D, Nattrass M. Effects of immunosuppressive agents on glucose metabolism: implication for the development of post-transplant diabetes mellitus. Clin Immunother 1995; 4: 103.